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In the current issue of Journal of Headache and Pain,
Tfelt-Hansen [1] suggests that calcitonin gene-related
peptide (CGRP) receptor antagonists (CGRP-RA) offer
relief to only a fraction of patients. To support his
hypothesis, he points out that only around two-thirds of
migraineurs receiving intravenous (IV) olcegepant achieved
pain relief in 2 h, and 46% of patients had pain relief in 1 h
[2], figures that are lower than previously reported values
for subcutaneous sumatriptan [3]. He also considers that
the therapeutic gain for oral telcagepant 300 mg [4, 5] was
modest. He concludes by saying that ‘‘…there is most
likely an inherent limit to the response one can expect
from CGRP receptor antagonists, such as olcegepant
and telcagepant, in the acute treatment of migraineurs as a
group.’’
The issues raised by Dr. Tfelt-Hansen are certainly of
interest and may be expanded outside the CGRP-RA class.
In other words, is there an inherent limit to acute migraine
treatment efficacy overall? Before sharing our opinion on
this matter, a few considerations on the topic are warranted.
First, endpoints used in acute migraine trials do not
measure the effectiveness of a drug for individual patients.
Instead, these endpoints measure the effectiveness of the
drug for a given population (e.g. 2 h pain free is a measure
of the proportion of patients that are rendered pain free at
2 h). In other words, if drug A is showed to be 5% more
effective than drug B, the conclusion is that 5% more
patients are likely to respond to drug A versus drug B, but
no conclusions can be drawn about the magnitude of
response in an individual patient. Indeed, on an individual
patient basis, it may very well be that drug B provides
greater benefit than drug A.
Second, the author bases his arguments on the fact that
2 h pain-free and pain-relief rates for olcegepant and
telcagepant are ‘‘not impressive’’, when compared to the
triptans. This is questionable. Around 66% of those
receiving IV olcegepant had pain relief. For telcagepant, in
a head-to-head phase 3 trial, 2-h efficacy was similar to the
efficacy of zolmitriptan 5 mg, a very effective triptan [4].
Nonetheless, as stated above, this simply means that when
comparing groups, similar proportions of patients respon-
ded to telcagepant and zolmitriptan (for the primary end-
point). It may be that patients responding to telcagepant
have different characteristics than, or benefit differently
from, patients responding to zolmitriptan.
Third, although responses at 2 h are certainly clinically
meaningful, are endorsed by the Clinical Trial Guidelines
of the International Headache Society [6], and are accepted
by the regulatory agencies, it is still not clear whether these
endpoints are the most important for patients [7]. Indeed, as
migraine attacks may last many hours and may recur fol-
lowing initial relief, endpoints measuring sustained relief
of pain are of importance. Accordingly, when evaluating
whether migraine medications have a ceiling effect it is
important to consider the parameters to be assessed, rather
than relying solely on 2-h endpoints. Studies assessing
patient’s preference are of importance in order to validate
the use of endpoints in terms of patients’ perceptions of
benefits [8]. Patients may define efficacy in terms that are
individual, largely variable from one patient to the other,
and may encompass several attributes of a drug (e.g., speed
of efficacy, duration of efficacy, tolerability, ease of use,
efficacy on associated symptoms, etc.) [9–12].
While the triptans have a well established mechanism of
action and clinical profile, the science beyond the new class
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of the CGRP-RA is just emerging, and the relative advan-
tages of one class over the other are still to be defined.
Nonetheless, as previously mentioned, the core question of
Dr. Tfelt-Hansen is relevant. Is there an inherent limit to
CGRP-RA acute treatment efficacy? We would suggest that
there is but, equally, that there is an inherent limit to the
efficacy of other classes of acute treatment including the
triptans. Migraine is a complex, multisymptomatic disorder,
influenced by genetic and environmental factors, with
clinical manifestations that vary considerably within attacks
and across patients [13]. Several neurotransmitters and
neuromediators are involved in migraine pathophysiology,
and migraine is the ultimate result of a complex neural
network dysfunction that leads to an over-sensitive brain
[13]. Different patients will certainly respond differently to
different classes of medications [14], and while some
patients respond to triptans, some do not. The same is true
for other classes of medications, and will surely be the same
for the CGRP-RA class. Large unmet migraine treatment
needs still exist and some of them should be addressed by
the class of CGRP-RA (e.g., triptan failures, contraindica-
tions to triptans, patients with risk factors for cardiovascular
disorders or using serotoninergic medications) [15, 16].
Given the complex pathophysiology of migraine, no single
drug is expected to treat all patients and this fact motivates,
and should continue motivating, the development of new
classes of migraine drugs.
Conflict of interest Dr. Bigal and Dr. Ho are full-time employees of
Merck Research Laboratories. They own stock and stock options from
Merck.
References
1. Tfelt-Hansen P (2009) Is there an inherent limit to the efficacy of
calcitonin-gene related peptide receptor antagonists in acute
migraine treatment? A comment. J Headache Pain. doi:10.1007/
s10194-009-0157-8
2. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U
et al (2004) Calcitonin gene-related peptide receptor antagonist
BIBN 4096 BS for the acute treatment of migraine. N Engl J Med
350(11):1104–1110
3. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in
migraine: a comparative review of pharmacology, pharmacoki-
netics and efficacy. Drugs 60(6):1259–1287
4. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X et al
(2008) Efficacy and tolerability of MK-0974 (telcagepant), a new
oral antagonist of calcitonin gene-related peptide receptor, com-
pared with zolmitriptan for acute migraine: a randomised, pla-
cebo-controlled, parallel-treatment trial. Lancet 372(9656):2115–
2123
5. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ et al
(2008) Randomized controlled trial of an oral CGRP receptor
antagonist, MK-0974, in acute treatment of migraine. Neurology
70(16):1304–1312
6. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD,
Goadsby PJ et al (2000) Guidelines for controlled trials of drugs
in migraine, 2nd edn. Cephalalgia 20(9):765–786
7. Lipton RB, Bigal ME, Goadsby PJ (2004) Double-blind clinical
trials of oral triptans vs. other classes of acute migraine medi-
cation—a review. Cephalalgia 24(5):321–332
8. Solomon J (2008) How strategies for managing patient visit time
affect physician job satisfaction: a qualitative analysis. J Gen
Intern Med 23(6):775–780
9. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C
(2007) Satisfaction with current migraine therapy: experience
from 3 centers in US and Sweden. Headache 47(4):475–479
10. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton
RB (2007) Patterns of diagnosis and acute and preventive treat-
ment for migraine in the United States: results from the American
Migraine Prevalence and Prevention study. Headache 47(3):355–
363
11. Ifergane G, Wirguin I, Shvartzman P (2006) Triptans—why
once? Headache 46(8):1261–1263
12. Bigal M, Krymchantowski AV, Lipton RB (2009) Barriers to
satisfactory migraine outcomes. What have we learned, where do
we stand? Headache 49:1028–1041
13. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current
understanding and treatment. N Engl J Med 346(4):257–270
14. Lipton RB, Cutrer FM, Goadsby PJ, Ferrari MD, Dodick DW,
McCrory D et al (2005) How treatment priorities influence triptan
preferences in clinical practice: perspectives of migraine suffer-
ers, neurologists, and primary care physicians. Curr Med Res
Opin 21(3):413–424
15. Recober A, Russo AF (2007) Olcegepant, a non-peptide CGRP1
antagonist for migraine treatment. IDrugs 10(8):566–574
16. Tepper SJ, Cleves C (2009) Telcagepant, a calcitonin gene-
related peptide antagonist for the treatment of migraine. Curr
Opin Investig Drugs 10(7):711–720
394 J Headache Pain (2009) 10:393–394
123
